An interventional study of Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF in Inflammatory Markers Changes in Response to Extra-corporeal Membrane Oxygenator Decannulation, sponsored by Hamad Medical Corporation. Status unknown at 2 sites in Qatar. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-19.
Sponsored by Hamad Medical Corporation · Not applicable, Interventional, and Screening
Extracorporeal membrane oxygenation (ECMO) aim at providing cardiac, respiratory support, or both. The use of ECMO could be associated with systemic inflammatory response syndrome (SIRS) at the time of initiation or the time of decannulation. There is an existing evidence to state that clinical criteria of SIRS accompany decannulation. We aim at proving this relation through studying the inflammatory markers changes before and after decannulation. The investigators will study all participants who require ECMO support in the heart hospital, all patient will be subjected to clinical evaluation of the SIRS criteria plus studying the inflammatory makers that will include IL1, IL2, IL6 and TNF before and after decannulation. Participants will be divided based on the SIRS criteria into 2 groups and both groups will be compared using Chi-Square analysis (Fisher tests if small sample size) or two tailed t-test, as appropriate
Hamad Medical Corporation is the lead sponsor of 133 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS)
Diagnostic Test: Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF
Patients will be grouped according to the presence or absence of SIRS criteria into group II (Non-SIRS)
Diagnostic Test: Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF
1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
Cytokine changes
Cytokines changes: Interleukins (IL); IL1, IL2, IL6 and TNF 1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
Time frame: 2 years
Length of stay in ICU
Time frame: First 48 hours after ECMO initiation
Length of mechanical ventilation
Time frame: First 48 hours after ECMO initiation
Plan to share: No
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamad Medical Corporation